Helix BioPharma (OTCMKTS:HBPCF) Issues Quarterly Earnings Results

Helix BioPharma (OTCMKTS:HBPCF) posted its earnings results on Monday. The company reported ($0.02) EPS for the quarter, Zacks reports.

Helix BioPharma Price Performance

OTCMKTS:HBPCF opened at $0.45 on Tuesday. The stock has a market capitalization of $22.30 million, a price-to-earnings ratio of -3.50 and a beta of 0.06. Helix BioPharma has a 52 week low of $0.45 and a 52 week high of $0.92. The firm has a 50 day moving average of $0.62 and a 200 day moving average of $0.49.

Helix BioPharma Company Profile

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.